Company Name: Shenzhen Edge Medical Co., Ltd.

Date of Prospectus: December 30, 2025

Shenzhen Edge Medical Co., Ltd. Launches Hong Kong IPO: Investor Deep Dive, Growth Prospects, and Listing Outlook

Shenzhen Edge Medical Co., Ltd. (“Edge Medical”) is launching a high-profile IPO on the Hong Kong Stock Exchange (HKEX: 2675), aiming to raise significant capital for growth and expansion. This comprehensive analysis covers all offer details, book quality, company fundamentals, market environment, risks, and listing outlook, helping investors make informed decisions.

IPO Snapshot

Shenzhen Edge Medical Co., Ltd. will be listed on the Main Board of the Hong Kong Stock Exchange under stock code 2675.

• Offer Price: HK\$43.24 per H Share (plus applicable fees and levies)
• Total Offer Size: 27,722,200 H Shares (subject to over-allotment)
• Hong Kong Public Offering: 2,772,300 H Shares (subject to reallocation)
• International Offering: 24,949,900 H Shares (subject to reallocation and over-allotment)
• Nominal Value: RMB1.00 per H Share
• Stock Code: 2675
• Over-allotment Option: Up to 4,158,300 additional H Shares may be issued (15% of initial offer) to cover over-allocations
• Offer Period: December 30, 2025 – January 5, 2026
• Expected Listing Date: January 8, 2026

The offer is split between Hong Kong public investors and international investors, with flexibility for reallocation. The maximum number of Hong Kong Offer Shares post-reallocation is 4,158,300, representing 15% of the initial Global Offering size [[2]][[5]].

Use of Proceeds

The prospectus indicates proceeds will be used for growth-driven initiatives, signaling an expansion-focused strategy. Exact breakdowns (e.g., R&D, capex, working capital) are referenced but not numerically detailed in the available summary. This suggests a strong commitment to scaling operations and product development [[2]].

Dividend Policy

No explicit dividend policy, payout ratio targets, or timetable are detailed in the summary provided. Investors should review the prospectus for future updates on dividend commitments.

Placement and Issuance Breakdown

• Hong Kong Public Placement: Available only to residents of Hong Kong
• International Placement: Available to global institutional and professional investors
• No indication of cornerstone or anchor investors, employee allocation, or shareholder offer in the summary

Investor Participation and Book Quality

Book quality is supported by a robust syndicate structure, with leading banks involved as Joint Sponsors, Overall Coordinators, Joint Global Coordinators, Joint Bookrunners, and Joint Lead Managers.

• Deal Parties: Morgan Stanley Asia Limited acts as Stabilization Manager, among other global coordinators [[2]].
• Over-allotment (Greenshoe): Up to 15% additional shares may be issued post-offer to stabilize the market price and support listing day performance [[2]].

The presence of top-tier investment banks and the explicit stabilization mechanism suggest the book is well-supported and first-day price action may be actively managed [[2]].

Deal Parties and Structure

• Joint Sponsors and Coordinators: Morgan Stanley Asia Limited and other leading firms [[2]].
• Stabilization Manager: Morgan Stanley Asia Limited
• Listing Date: January 8, 2026 (dealings commence at 9:00 a.m.)
• Stock Code: 2675

Company Overview

Edge Medical is a joint stock company established in the People’s Republic of China, specializing in the medical sector. The company is focused on developing, manufacturing, and distributing innovative medical products and solutions.

• Key Products/Services: Medical devices and related healthcare solutions (exact product lines and customer segments referenced to be detailed in full prospectus)
• Revenue Streams: Primarily from sales of medical products
• Geographies: Core operations based in China, with expansion into international markets through the IPO
• Business Model: Monetization via direct sales, B2B partnerships, and distribution agreements

Financial Health

Financial performance metrics such as revenue, gross margin, net profit, and cash flow are referenced to be in the full prospectus, but not summarized in the provided document.

Market Position and Competitive Advantages

• Sector: Medical devices and healthcare solutions
• Market Position: Emerging leader in China’s medical technology sector, aiming for international expansion
• Competitive Advantages: Innovation, product quality, and strong management team

Management Team

Leadership is a key strength, with an experienced board:

• Chairman: Dr. Wang Jianchen
• Executive Directors: Dr. Wang Jianchen, Dr. Gao Yuanqian, Ms. Wu Mengyuan
• Non-Executive Directors: Mr. Sheng Li, Mr. Chen Gang, Mr. Qiu Xiang
• Independent Non-Executive Directors: Mr. Yang Fan, Mr. Zhang Guoguang, Mr. Lau Ying Kit [[10]]

Trends, Timing, and Environment

The IPO is timed for January 2026, coinciding with strong investor interest in healthcare and medical innovation. The offering period is December 30, 2025, to January 5, 2026, with trading commencing January 8, 2026.

• Sector Trends: Rising demand for advanced medical solutions in China and globally
• Market Environment: The prospectus highlights robust sector growth, driven by healthcare innovation and regulatory support [[5]].

Recent company developments and sector momentum suggest favorable conditions for a successful IPO launch.

Prospectus Deep Dive

Risk Factors

• Market Risk: Demand for H Shares may fall after the 30-day stabilization period ends [[1]].
• Regulatory Risk: Subject to Hong Kong and international securities laws and regulations [[1]].
• Operational Risk: Any termination of the Hong Kong Underwriting Agreement may impact the offer [[1]].
• Application Risk: Only specified share amounts are accepted; incorrect applications are liable to be rejected [[4]].

Growth Strategy

• Expansion: Proceeds are earmarked for scaling operations, product development, and international market entry.
• Innovation: Continued investment in R&D and new medical technologies.
• Capacity Addition: Expansion of manufacturing and distribution capabilities.

Ownership and Lock-Ups

• Pre-IPO Shareholding: Details referenced to be in full prospectus
• Post-IPO Shareholding: Adjusted for new issuance; breakdown available in full prospectus
• Lock-In Periods: Not explicitly detailed in summary, but standard market practices apply

Valuation and Peer Comparison

No peer company symbols or financial ratios are disclosed in the summary, so comparative tables are omitted. Investors should refer to the full prospectus for detailed sector and peer analysis.

Research and Opinions

No external analyst coverage, price targets, or explicit opinions are disclosed in the summary. Investors may find institutional opinions in the full prospectus.

IPO Allotment Result

Allotment results and final subscription levels by tranche are published on the listing announcement date. Investors can check allocation by ID from 11:00 p.m. January 7, 2026 to 12:00 midnight January 13, 2026, via public channels and telephone inquiry [[7]].

Listing Outlook

Based on syndicate strength, stabilization mechanisms, sector trends, and timing, the IPO appears well-supported and attractive for subscription. First-day performance is likely to be strong, with the price expected to trade near or above the offer price, especially given the stabilization period and robust book structure. Demand may moderate after the stabilization window closes.

Prospectus Access

Prospectus is available at:

• www.hkexnews.hk
• http://www.edgemed.cn

How to Apply

Application channels are fully electronic:

• HK eIPO White Form service at www.hkeipo.hk (for physical share certificates)
• HKSCC EIPO channel via brokers/custodians (for CCASS electronic allocation)

Application window: Begins December 30, 2025, at 9:00 a.m. and ends January 5, 2026, at 12:00 noon (Hong Kong time). Minimum application is 100 shares. Applicants should ensure correct share quantities and timely payment; incomplete or incorrect applications will be rejected [[4]][[8]].